Compare STEX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | SERA |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 75.2M |
| IPO Year | 2013 | 2021 |
| Metric | STEX | SERA |
|---|---|---|
| Price | $0.49 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.1M | 16.1K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | $18,000.00 | ★ $81,000.00 |
| Revenue This Year | N/A | $177.78 |
| Revenue Next Year | $1,314.29 | $755.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.48 | $1.56 |
| 52 Week High | $6.50 | $3.95 |
| Indicator | STEX | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 50.86 |
| Support Level | N/A | $1.96 |
| Resistance Level | $1.07 | $2.07 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.10 | 28.57 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.